Lixian Wu Wu | Pharmacology | Best Researcher Award

Posted on by ScienceFather

Prof. Lixian Wu Wu | Pharmacology | Best Researcher Award

Vice Dean at Fujian Medical University, China.

Dr. Lixian Wu 🎓 is an accomplished pharmacologist from Fujian, China, with over 20 years of experience in anticancer drug research 💊. Her groundbreaking work includes DNA repair mechanisms 🧬, tumor microenvironment interactions 🧫, and PROTAC-based drug design 🧪. A distinguished researcher and mentor, she has led multiple national projects 📑, secured five patents 📘, and published influential scientific papers 📚. As a doctoral advisor, she has guided numerous Ph.D. and master’s students 🎓. Dr. Wu’s dedication to innovation and excellence has earned her the title of Fujian Provincial High-Level Talent 🌟.

Professional Profile:

Scopus

Suitability for Best Researcher Award – Dr. Lixian Wu

Dr. Lixian Wu is highly suitable for the Best Researcher Award due to her sustained excellence in anticancer pharmacology research, innovative drug discovery, and academic mentorship over the past two decades. Her ability to translate complex molecular mechanisms into potential therapeutic strategies—such as PROTAC-based compounds and immune-targeted therapies—demonstrates a deep and ongoing commitment to impactful, high-quality science. She has also contributed significantly to China’s biomedical innovation ecosystem through patents, national-level research leadership, and talent cultivation.

🎓 Education & Experience

  • 🎓 Bachelor’s Degree in Clinical Medicine – Fujian Medical University, China

  • 🧪 Master’s Degree (M.D.) in Pharmacology – Fujian Medical University

  • 🧬 Ph.D. in Pharmacology – Fujian Medical University

  • 🧠 20+ years of research experience in anticancer pharmacology

  • 🧑‍🏫 Doctoral Tutor mentoring 8 Ph.D. and 20 Master’s students

  • 📋 Principal Investigator for 4 National Natural Science Foundation projects

📈 Professional Development 

Dr. Wu has continually advanced her professional journey through innovative research and academic leadership 🌐. She has synthesized and screened high-efficacy anticancer compounds via PROTAC technology 🧪, explored immune-based cancer therapy through NKT cell modulation 🔬, and discovered novel feedback loops in DNA repair pathways 🧬. She remains actively engaged in national-level scientific funding programs 📑 and contributes to the field through patents and impactful publications 📚. Her mentorship has nurtured the next generation of pharmacologists 👩‍🔬👨‍🔬, enhancing China’s scientific landscape. Her evolving research and professional expertise position her as a thought leader in oncology drug discovery 🌟.

🧪 Research Focus Category

Dr. Wu’s research primarily centers on anticancer pharmacology 💊, particularly the molecular mechanisms of cancer progression and therapy 🧬. Her work targets DNA repair pathways, unveiling the regulatory roles of NF-kB and PARP1 in tumor survival 🔍. She also explores the tumor microenvironment, focusing on the immune system’s role in fighting cancer, especially through NKT cells 🧫. Leveraging PROTAC technology, she has developed degradation-based drug strategies with high therapeutic potential ⚗️. Her multi-dimensional approach places her research at the crossroads of immunopharmacology, molecular biology, and drug design, making a significant impact on cancer therapeutics 🔬.

🏅 Awards and Honors

  • 🏆 Fujian Provincial High-Level Talent recognition

  • 📑 Principal Investigator of 4 National Natural Science Foundation of China (NSFC) grants

  • 🧪 Holder of 5 Chinese Invention Patents in anticancer drug development

  • 📚 Author of several influential SCI-indexed research papers

  • 🎓 Mentor to 8 Ph.D. and 20 Master’s students

Publication Top Notes

🧬 Amiloride reduces fructosamine-3-kinase expression to restore sunitinib sensitivity in renal cell carcinoma – iScience (2024) | Cited by: 1

💊 Ferroptosis boosted oral cancer photodynamic therapy by carrier-free Sorafenib-Ce6 self-assembly nanoparticles – Journal of Controlled Release (2024) | Cited by: 22

🔬 Discovery of X10g as a selective PROTAC degrader of Hsp90α protein for treating breast cancer – European Journal of Medicinal Chemistry (2023) | Cited by: 5

🧪 Synthesis of Novel Dual Target Inhibitors of CDK12 and PARP1 and Their Antitumor Activities in HER2-Positive Breast Cancers – ACS Omega (2023) | Cited by: 3

Conclusion

Dr. Lixian Wu exemplifies the qualities of a Best Researcher Award recipient through her innovative research, national and international impact, and mentorship leadership. Her contributions to anticancer drug design and her role in shaping China’s research capacity place her in the top tier of biomedical researchers. She is not only a leader in her field but also a beacon for emerging scientists in pharmacology.

Prof. Dr. Yukihiko Sugimoto | Pharmacology Awards | Best Researcher Award

Posted on by ScienceFather

Prof. Dr. Yukihiko Sugimoto | Pharmacology Awards | Best Researcher Award

Prof. Dr. Yukihiko Sugimoto,Kumamoto University Graduate School of Pharmaceutical Sciences,Japan

Yukihiko Sugimoto is a distinguished biochemist currently serving as a Professor of Biochemistry at Kumamoto University, Japan. Born on November 20, 1965, in Kyoto, Japan, he earned his Ph.D. from Kyoto University in 1994 with a thesis on prostaglandin E receptors. His research, which spans over three decades, focuses on the biochemical and physiological roles of prostaglandins and their receptors. Professor Sugimoto has been recognized with several prestigious awards, including the Young Scientist Award from both The Japanese Pharmacological Society and The Japanese Biochemical Society. His notable publications include influential papers on the role of prostaglandins in various biological processes and diseases.

Professional Profile:

Scopus

Orcid

Summary of Suitability:

Yukihiko Sugimoto stands out as a strong candidate for the Research for Best Researcher Award due to his substantial contributions to the field of biochemistry and pharmacology. His extensive research portfolio, spanning over three decades, showcases significant advancements in understanding prostaglandin receptors and their implications in various physiological and pathological processes.

🎓Education:

Professor Yukihiko Sugimoto completed his undergraduate studies in Pharmaceutical Sciences at the Faculty of Pharmaceutical Sciences, Kyoto University, from 1984 to 1988. He then pursued a Master’s degree in Pharmaceutical Sciences at the Department of Physiological Chemistry, Graduate School of Pharmaceutical Sciences, Kyoto University, between 1988 and 1990. Following this, he obtained his Ph.D. in 1994 from the same department, with his thesis focusing on “A Study for Structure and Function of Prostaglandin E Receptors,” under the supervision of Professor Atsushi Ichikawa

🏢Work Experience:

Professor Yukihiko Sugimoto began his academic career as an Assistant Professor of Physiological Chemistry at Kyoto University, where he worked from 1992 to 1997. He then advanced to the role of Associate Professor of Physiological Chemistry at the same institution, serving from 1997 to 2009. Since 2009, he has been a Professor of Biochemistry at Kumamoto University, continuing his influential research and contributions to the field.

🏅Awards:

Professor Yukihiko Sugimoto has received notable recognition for his contributions to the field of biochemistry. He was honored with the Young Scientist Award by The Japanese Pharmacological Society in 1999 and again by The Japanese Biochemical Society in 2005. These awards acknowledge his significant research achievements and impact on the scientific community.

Publication Top Notes:

  • “The Concise Guide to PHARMACOLOGY 2023/24: G Protein-Coupled Receptors”
    • Citations: 89
  • “Prostaglandin E2 Receptor Ptger4b Regulates Female-Specific Peptidergic Neurons and Female Sexual Receptivity in Medaka”
    • Citations: 2
  • “Metabolic Regulation in Adipocytes by Prostanoid Receptors”
  • “Effects of an ω3 Fatty Acid-Biased Diet on Luteolysis, Parturition, and Uterine Prostanoid Synthesis in Pregnant Mice”
    • Citations: 1
  • “Amakusamine from a Psammocinia sp. Sponge: Isolation, Synthesis, and SAR Study on the Inhibition of RANKL-Induced Formation of Multinuclear Osteoclasts”
    • Citations: 8

 

 

 

Mr. Muhammad Yaseen | Pharmacology Awards | Best Researcher Award

Posted on by ScienceFather

Mr. Muhammad Yaseen | Pharmacology Awards | Best Researcher Award

Mr. Muhammad Yaseen , University of Swat , Pakistan

Muhammad Yaseen, currently pursuing his Master of Philosophy at the Institute of Chemical Sciences, University of Swat, Pakistan, holds a Bachelor of Science from Govt PG Jahanzeb College, Saidu Sharif Swat. His research interests include the synthesis of natural organic products and nanomaterials, with a focus on cancer therapeutics and molecular docking. With over a decade of experience in the field, Yaseen has demonstrated expertise in molecular dynamics simulations and has contributed significantly to the exploration of various therapeutic avenues, as evidenced by his numerous publications in reputable journals.

Professional Profile:

Orcid

Education:

Muhammad Yaseen is currently engaged in the pursuit of his Master of Philosophy at the Institute of Chemical Sciences, situated within the esteemed University of Swat, located in Pakistan. Building upon his foundational education, Yaseen completed his Bachelor of Science degree at Govt PG Jahanzeb College, nestled in Saidu Sharif Swat. With an unwavering commitment to academic and intellectual growth, he is dedicated to furthering his understanding and expertise in chemical sciences. His academic journey reflects a profound dedication to scholarly pursuits, particularly in the realm of bioinformatics and drug discovery.

Work Experience:

Muhammad Yaseen is currently immersed in his academic journey, pursuing a Master of Philosophy at the Institute of Chemical Sciences, a prestigious institution housed within the University of Swat, Pakistan. His dedication to academic excellence and intellectual growth is evident in his ongoing pursuit of higher education. Yaseen’s educational foundation was laid with his Bachelor of Science degree, which he successfully completed at Govt PG Jahanzeb College in Saidu Sharif Swat.

Publication Top Notes:

  1. Title: Crops and people: the dangers and potential benefits of pesticides
    • Journal: Cogent Food & Agriculture
    • Publication Date: 2024-12-31
    • Article Type: Journal article
    • DOI: 10.1080/23311932.2024.2334096
    • Part of ISSN: 2331-1932
  2. Exploring the Therapeutic Potential of Petiveria alliacea L. Phytochemicals: A Computational Study on Inhibiting SARS-CoV-2’s Main Protease (Mpro)
  3. Investigating Potential Cancer Therapeutics: Insight into Histone Deacetylases (HDACs) Inhibitions
    • Journal: Pharmaceuticals
    • Publication Date: 2024-03-29
    • Article Type: Journal article
    • DOI: 10.3390/ph17040444
  4. Discovery of Bacterial Key Genes from 16S rRNA-Seq Profiles That Are Associated with the Complications of SARS-CoV-2 Infections and Provide Therapeutic Indications
    • Journal: Pharmaceuticals
    • Publication Date: 2024-03-28
    • Article Type: Journal article
    • DOI: 10.3390/ph17040432
  5. Silico Analysis of Mutations in Quinolone Resistance Determinant Region for Flouroquinolone Resistance in <em>Salmonella typhi</em>